Vitreoretinopathy

Aldeyra Therapeutics Schedules Webcast and Conference Call to Report First-Quarter 2021 Financial Results and Discuss Recent Business Highlights

Retrieved on: 
Thursday, April 29, 2021
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, Vitreoretinopathy, Dihydrofolate reductase inhibitor, Reductase, Dihydrofolate reductase, Chemistry, Branches of biology

b'Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m.

Key Points: 
  • b'Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m.
  • ET Thursday, May 6, 2021 to report financial results for the quarter ended March 31, 2021 and discuss recent business highlights.\nThe dial-in numbers are (866) 211-4098 for domestic callers and (647) 689-6613 for international callers.
  • The company\xe2\x80\x99s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy.
  • For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn , Facebook , and Twitter .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210429005131/en/\n'

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE Clinical Trial

Retrieved on: 
Monday, April 26, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Vitreoretinopathy, Dihydrofolate reductase inhibitor, Reductase, Dihydrofolate reductase, Chemistry, Branches of biology

The Conference ID is 7578367.

Key Points: 
  • The Conference ID is 7578367.
  • A live, listen-only audio webcast of the conference call can be accessed on the investor relations page of Aldeyra's corporate website at ir.aldeyra.com .\nAfter the live webcast, the event will remain archived on the Aldeyra Therapeutics website for 90 days.\nAldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases.
  • The company\xe2\x80\x99s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy.
  • For more information, visit https://www.aldeyra.com and follow us on LinkedIn , Facebook , and Twitter .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210426005803/en/\n"

Aldeyra Therapeutics to Advance ADX-1612, an Investigational New HSP90 Inhibitor with Potential Nanomolar Potency Against SARS-CoV-2, to Clinical Testing for COVID-19; ADX-629 Accepted for BARDA CoronaWatch Meeting

Retrieved on: 
Wednesday, May 20, 2020
Biotechnology, General Health, Infectious diseases, Health, Clinical trials, Vitreoretinopathy, Dihydrofolate reductase inhibitor, Reductase, Dihydrofolate reductase, Respiratory compromise, Retinopathy, Branches of biology

Aldeyra also announced that ADX-629, a novel orally administered investigational RASP inhibitor, has been granted a BARDA CoronaWatch meeting.

Key Points: 
  • Aldeyra also announced that ADX-629, a novel orally administered investigational RASP inhibitor, has been granted a BARDA CoronaWatch meeting.
  • Severe COVID-19 is characterized by cytokine release syndrome, which may lead to respiratory compromise, often including the requirement for mechanical ventilation.
  • Aldeyra will host a conference call to discuss this announcement today, Wednesday, May 20, 2020, at 8:00 a.m.
  • The companys clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy.

Global Proliferative Vitreoretinopathy (PVR) Pipeline Study, H1 2020

Retrieved on: 
Monday, April 27, 2020
Vitreoretinopathy, Proliferative vitreoretinopathy, PVR, Retinopathy

DUBLIN, April 27, 2020 /PRNewswire/ -- The "Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 27, 2020 /PRNewswire/ -- The "Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Proliferative Vitreoretinopathy (PVR) and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Proliferative Vitreoretinopathy (PVR) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Formulate corrective measures for pipeline projects by understanding Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Aldeyra Announces Strategic Prioritization of Late-Stage Clinical Pipeline in Ocular Disease

Retrieved on: 
Thursday, March 12, 2020
Biotechnology, Health, Pharmaceutical, Optical, Clinical trials, Ophthalmology, Medical specialties, Medicine, Vitreoretinopathy, Allergic conjunctivitis, Retinopathy

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), today announced strategic prioritization of late-stage ocular disease programs in allergic conjunctivitis, dry eye disease, and proliferative vitreoretinopathy.

Key Points: 
  • Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), today announced strategic prioritization of late-stage ocular disease programs in allergic conjunctivitis, dry eye disease, and proliferative vitreoretinopathy.
  • In conjunction with the strategic prioritization, Aldeyra appointed ophthalmology drug development expert James A. Gow, M.D., as Senior Vice President of Clinical Development.
  • The initiatives to prioritize Aldeyras ocular portfolio are expected to extend the companys cash runway through the end of 2021.
  • Consistent with our strategic prioritization of ocular disease, we are pleased to welcome Dr. Gow, an established leader in the development of ophthalmic therapeutics, as our new Senior Vice President of Clinical Development.

Aldeyra Therapeutics Announces First Patient Enrolled in the Phase 3 GUARD Trial for Prevention of Proliferative Vitreoretinopathy

Retrieved on: 
Thursday, December 19, 2019
Biotechnology, Health, Pharmaceutical, Optical, Clinical trials, Health, Proliferative vitreoretinopathy, PVR, Clinical trial, Vitreoretinopathy, Medicine

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced enrollment of the first patient into the Phase 3 GUARD Trial of ADX-2191 for the prevention of proliferative vitreoretinopathy (PVR).

Key Points: 
  • Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced enrollment of the first patient into the Phase 3 GUARD Trial of ADX-2191 for the prevention of proliferative vitreoretinopathy (PVR).
  • Today, the only option for patients who develop PVR is surgery, which fails in a significant number of cases.
  • The GUARD Trial is a two-part, multi-center, randomized, controlled, adaptive Phase 3 clinical trial evaluating the efficacy of intravitreal injections of ADX-2191 versus standard-of-care for the prevention of PVR.
  • In September 2019, the U.S. Food and Drug Administration (FDA) granted fast track designation to ADX-2191 for the prevention of PVR.

Aldeyra Therapeutics Reports Third-Quarter 2019 Financial Results and Provides Updates on Anticipated Clinical Milestones

Retrieved on: 
Thursday, November 7, 2019
Biotechnology, Pharmaceutical, Optical, Health, Health, Medical specialties, Medicine, Food and Drug Administration, Drug discovery, Medical statistics, Pharmaceutical industry, Allergic conjunctivitis, Allergology, Vitreoretinopathy, Clinical trial

Dry Eye Disease: Part 1 of Adaptive RENEW Phase 3 Clinical Trial Scheduled for Completion in the Fourth Quarter of 2019.

Key Points: 
  • Dry Eye Disease: Part 1 of Adaptive RENEW Phase 3 Clinical Trial Scheduled for Completion in the Fourth Quarter of 2019.
  • In October, the company presented the results of the ALLEVIATE Phase 3 clinical trial in allergic conjunctivitis at the American Academy of Ophthalmology Annual Meeting in San Francisco.
  • Proliferative Vitreoretinopathy: Part 1 of the Adaptive GUARD Phase 3 Clinical Trial Scheduled to Initiate in the Fourth Quarter of 2019.
  • Post-transplant Lymphoproliferative Syndrome: Phase 2 Clinical Trial of ADX-1612 Scheduled to Initiate in the Fourth Quarter of 2019.

Aldeyra Therapeutics Receives Fast Track Designation for ADX-2191 for the Prevention of Proliferative Vitreoretinopathy

Retrieved on: 
Tuesday, September 24, 2019
Biotechnology, Pharmaceutical, Optical, FDA, Health, Clinical trials, Articles, Health, Life sciences, PVR, Vitreoretinopathy, Proliferative vitreoretinopathy, Retinopathy, Fast track, Orphan drug

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to ADX-2191 for the prevention of proliferative vitreoretinopathy (PVR).

Key Points: 
  • Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to ADX-2191 for the prevention of proliferative vitreoretinopathy (PVR).
  • Fast track designation is an important milestone for our retinal disease platform, and promising news for PVR patients, said Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra.
  • The fast track designation is designed to facilitate the development and expedite the review of drugs that treat serious conditions, potentially accelerating patient access to new therapies.
  • ADX-2191, an intravitreal formulation of methotrexate, has been granted orphan drug designation for the prevention of proliferative vitreoretinopathy (PVR).

Aldeyra Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, August 28, 2019
Biotechnology, Pharmaceutical, Optical, Health, General Health, Clinical trials, Medical specialties, Medicine, Organ systems, Vitreoretinopathy, Allergy, Allergic conjunctivitis, Retinopathy, Medication, Proliferative vitreoretinopathy

The Janney presentation will be webcast live and archived on the Investors section of the Aldeyra website, http://ir.aldeyra.com/ .

Key Points: 
  • The Janney presentation will be webcast live and archived on the Investors section of the Aldeyra website, http://ir.aldeyra.com/ .
  • Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases.
  • Aldeyra's lead investigational drug product candidates are first-in-class potential treatments in development for dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, and Sjgren-Larsson Syndrome.
  • The company is also developing other product candidates for retinal and systemic inflammatory diseases.

Aldeyra Therapeutics Announces Second Quarter 2019 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 8, 2019
Biotechnology, Pharmaceutical, Optical, Health, General Health, Clinical trials, Medical specialties, Medicine, Allergic conjunctivitis, Allergology, Conjunctivitis, Vitreoretinopathy

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced quarter ended June 30, 2019 financial results and provided a corporate update.

Key Points: 
  • Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced quarter ended June 30, 2019 financial results and provided a corporate update.
  • Allergic Conjunctivitis FDA Meeting Scheduled for Fourth Quarter to Confirm Design of Second Phase 3 Clinical Trial.
  • In March 2019, Aldeyra reported positive top-line results from the Phase 3 ALLEVIATE Trial of topical ocular reproxalap in allergic conjunctivitis, and plans to present full results of ALLEVIATE at the American Academy of Ophthalmology 2019 Annual Meeting in October 2019.
  • Proliferative Vitreoretinopathy the Adaptive Phase 3 GUARD Clinical Trial of ADX-2191 Expected to Initiate in the Fourth Quarter of 2019.